Evidence map›Paper›PMID 32046620›Full record

ArticleTherapeutic advances in respiratory disease

Eradication of

Anne M Akkerman-Nijland, Mina Yousofi, Bart L Rottier, Hester Van der Vaart, Johannes G M Burgerhof, Henderik W Frijlink, Daan J Touw, Gerard H Koppelman, Onno W Akkerman

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Therapeutic Interventions forJournal of clinical medicine · 2024
    Review
  4. Role of inhaled antibiotics in the era of highly effective CFTR modulators.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anne M Akkerman-NijlandDepartment of Paediatrics, University Medical Centre Groningen, Beatrix Children's Hospital, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, Groningen, 9713 GZ, the Netherlands.ORCID 0000-0002-7327-5422
Mina YousofiDepartment of Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Bart L RottierDepartment of Paediatric Pulmonology and Paediatric Allergology, University Medical Centre Groningen, Beatrix Children's Hospital, University of Groningen, Groningen, the Netherlands.
Hester Van der VaartDepartment of Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Johannes G M BurgerhofDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Henderik W FrijlinkDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
Daan J TouwUniversity of Groningen, University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands.
Gerard H KoppelmanDepartment of Paediatric Pulmonology and Paediatric Allergology, University Medical Centre Groningen, Beatrix Children's Hospital, University of Groningen, Groningen, the Netherlands.
Onno W AkkermanDepartment of Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsAdult CF patients with a

resultsIn total 27

conclusionEradication rates of DPI tobramycin are comparable with those for nebulized tobramycin reported in the literature. This study suggests that DPI tobramycin is an alternative to nebulized tobramycin for eradication of

trial registrationThe Medical Ethics Committee of the UMCG granted a waiver (METC2017-349), as they concluded that this study was not subject to the Medical Research Involving Human Subjects Act.

Indexed as

Administration, InhalationAdultAnti-Bacterial AgentsCystic FibrosisDry Powder InhalersFemaleHumansLungMaleMiddle AgedNebulizers and VaporizersPseudomonas aeruginosaPseudomonas InfectionsRespiratory Tract InfectionsRetrospective StudiesTobramycinAnti-Bacterial AgentsTobramycincystic fibrosisdry powder tobramycinPseudomonas aeruginosa

Identifiers

PMID32046620
PMCPMC7016310
OpenAlexW3006566421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.